ESR1 and breast cancer: In the TCGA breast cancer dataset, TTP-low tumors are twice as likely to be ER-negative (ER-) or PR-negative (PR-) versus TTP-high tumors, indicating that hormone therapies commonly used to block estrogen activity might be less effective at impairing the growth of breast tumors with low TTP expression (Fig. 4A).